{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(7)"],"submitter":["Blohmer JU"],"pubmed_abstract":["<h4>Importance</h4>Adjuvant denosumab might improve disease-free survival in hormone receptor (HR)-positive primary breast cancer (BC). The optimal neoadjuvant nab-paclitaxel schedule in terms of efficacy and safety is unclear.<h4>Objective</h4>To determine whether adding denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy (NACT) increases the pathological complete response (pCR) rate and which nab-paclitaxel schedule is more effective in the NACT setting.<h4>Design, setting, and participants</h4>The GeparX was a multicenter, prospective, open-label, phase 2b, 2 × 2 randomized clinical trial conducted by GBG and AGO-B at 38 German sites between February 2017 and March 2019. The analysis data set was locked September 4, 2020; analysis was completed November 13, 2020. Patie"],"journal":["JAMA oncology"],"pagination":["1010-1018"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9121303"],"repository":["biostudies-literature"],"pubmed_title":["Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial."],"pmcid":["PMC9121303"],"pubmed_authors":["Rhiem K","Seiler S","Hackmann J","Wullner MP","Warm M","Lubbe K","Jackisch C","Paulenz A","Frank M","Untch M","Loibl S","Renner S","Denkert C","Kummel S","Tesch H","Buchen S","Hofman M","Fasching PA","Seither F","Kuhn C","GBG and AGO-B","Hanusch C","Mahlberg R","Buckner U","Holms F","Radosa J","Decker T","Weigel M","Hartkopf A","Solbach C","Tome O","Krabisch P","Thomalla J","Reinisch M","Hofmann O","Noesselt T","Just M","Stotzer O","Kuhn W","Huober J","Kunz G","Schneeweiss A","Link T","Schilling J","Blohmer JU","Fehm T","Rom J","Jung C","Heinrich B","Nekljudova V","Wimberger P","Engels K","Simon E","Schmatloch S","Thill M"],"additional_accession":[]},"is_claimable":false,"name":"Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.","description":"<h4>Importance</h4>Adjuvant denosumab might improve disease-free survival in hormone receptor (HR)-positive primary breast cancer (BC). The optimal neoadjuvant nab-paclitaxel schedule in terms of efficacy and safety is unclear.<h4>Objective</h4>To determine whether adding denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy (NACT) increases the pathological complete response (pCR) rate and which nab-paclitaxel schedule is more effective in the NACT setting.<h4>Design, setting, and participants</h4>The GeparX was a multicenter, prospective, open-label, phase 2b, 2 × 2 randomized clinical trial conducted by GBG and AGO-B at 38 German sites between February 2017 and March 2019. The analysis data set was locked September 4, 2020; analysis was completed November 13, 2020. Patie","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2026-05-09T22:31:26.849Z","creation":"2024-11-07T10:25:45.848Z"},"accession":"S-EPMC9121303","cross_references":{"pubmed":["35588050"],"doi":["10.1001/jamaoncol.2022.1059"]}}